A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs PBT 434 (Primary)
- Indications Brain cancer; Neurodegenerative disorders; Parkinson's disease
- Focus Adverse reactions; First in man
- Acronyms PBT434-101
- Sponsors Prana Biotechnology
- 31 Jan 2019 According to a Prana Biotechnology media release, the company expects to complete the trial this year.
- 18 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Apr 2018 New trial record